usp30

USP30 inhibitor 11 (USP30-IN-11) is a selective USP30 inhibitor (IC50: 0.01 µΜ) that inhibits SVA and can be used in studies of cancer, mitochondrial dysfunction and Parkinson's.

USP30 inhibitor 18 is a selective USP30 inhibitor with an IC50 of 0.02 μM. USP30 inhibitor 18 increases protein ubiquitination and accelerates mitophagy[1]. [1]. Arthur F Kluge, et al. Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy. Bioorg Med Chem Lett. 2018 Aug 15;28(15):2655-2659.

USP30-I-1, a selective inhibitor of USP30, exhibits an IC50 of 94 nM. This compound is utilized in research into diseases characterized by impaired mitochondrial autophagy, specifically targeting USP30.

FT3967385 is a newly developed compound that functions as a USP30 inhibitor, emulating the genetic deficiency of USP30. This inhibition serves as a catalyst for the amplification of mitochondrial ubiquitylation through the PINK1-PARKIN pathway.

FT385 is a novel USP30 inhibitor, recapitulating genetic loss of USP30 and setting the trigger for PINK1-PARKIN amplification of mitochondrial ubiquitylation.

SB1-F-78 is an USP30 inhibitor.

MF-094 is a selective USP30 inhibitor with IC50 of 0.12 μM. MF-094 can increase protein ubiquitination and accelerate mitophagy.

MTX115325 (Example 1) is a brain-penetrant USP30 inhibitor with an IC 50 of 12 nM, administered orally and exhibiting neuroprotective properties. It enhances ubiquitination (EC 50 =32 nM) of TOM20, a mitochondrial outer membrane protein and USP30 substrate, thereby promoting mitophagy. Additionally, MTX115325 prevents dopaminergic neuron loss and maintains striatal dopamine [1].

ST-539 is an inhibitor of the deubiquitinating enzyme USP30, with an IC50 of 0.37 μM. It enhances the ubiquitination of mitochondrial proteins and induces mitophagy (autophagy), thereby regulating mitochondrial homeostasis. ST-539 is applicable for research in neurodegenerative diseases.